Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.

摘要: PURPOSE The modulation of fluorouracil (FU) by folinic acid (leucovorin [LV]) has been shown to be effective in terms tumor response rate patients with advanced colorectal cancer, but a meta-analysis nine trials previously published our group failed demonstrate statistically significant survival difference between FU and FU-LV. We present an update the meta-analysis, longer follow-up inclusion 10 newer trials. PATIENTS AND METHODS Analyses are based on individual data from 3,300 randomized 19 intent-to-treat basis. Two had multiple comparisons, leading total 21 pair-wise comparisons. doses were similar both arms 15% 33% higher FU-alone arm six more than 66% five RESULTS Overall analysis showed two-fold increase rates (11% for FU-LV v 21% 11% [corrected] alone; odds ratio, 0.53; 95% CI, 0.44 0.63; P <.0001) small overall benefit over alone (median survival, 11.7 10.5 months, respectively; hazards 0.90; 0.87 0.94; =.004), which primarily seen first year. observed interaction treatment dose FU, advantages being restricted was prescribed arms. CONCLUSION This updated demonstrates, large set, that improves compared this is consistent across various prognostic factors.